Gabapentin add-on treatment for drug-resistant focal epilepsy.
CONCLUSIONS: Gabapentin has efficacy as an add-on treatment in people with drug-resistant focal epilepsy, and seems to be fairly well-tolerated. However, the trials reviewed were of relatively short duration and provide no evidence for the long-term efficacy of gabapentin beyond a three-month period. The results cannot be extrapolated to monotherapy or to people with other epilepsy types. Further trials are needed to assess the long-term effects of gabapentin, and to compare gabapentin with other add-on drugs.
PMID: 33434292 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Panebianco M, Al-Bachari S, Hutton JL, Marson AG Tags: Cochrane Database Syst Rev Source Type: research
More News: Ataxia | Brain | Clinical Trials | Databases & Libraries | Epilepsy | Gabapentin | General Medicine | Headache | International Medicine & Public Health | Migraine | Neurology | Neurontin | Study | WHO